Zbigniew Nowecki
Head od Department
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Zbigniew Nowecki is the Head of the Department at the Maria Sklodowska-Curie National Research Institute of Oncology in Poland. His research primarily focuses on neoadjuvant therapy for breast cancer patients, examining its effects on surgical treatment and radiotherapy. His recent publications include studies on the preoperative treatment of breast cancer and its influence on subsequent medical procedures.
Articles (3)
Purpose: The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor–positive, HER2-negative (HR+/HER2−) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE. Patients and Methods: Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer–specific QOL questionnaire breast symptoms scale; health on a visual analog scale of the generic EuroQOL 5-level instrument; and the Hospital Anxiety and Depression Scale] were assessed. The prespecified primary HRQOL endpoint was physical functioning. Mean scores and time-categorical and prespecified linear-time repeated-measure models were used to evaluate HRQOL changes during treatment. Results: HRQOL was evaluated in all patients in the ribociclib plus NSAI ( n = 2,549) and NSAI alone ( n = 2,552) arms. Compliance was high in both arms (≈93%–97%). Mean scores did not differ meaningfully from baseline for any analyzed domain. Likewise, neither a meaningful change from baseline (in either treatment arm) nor a difference between arms was observed during treatment in the time-categorical, model-adjusted mean scores for any HRQOL domains—using published thresholds for interpreting longitudinal and between-group differences, with all values being within 0.5 SD of their baseline values. Linear-time regression analysis confirmed these findings. Conclusions: These analyses of NATALEE show that adding adjuvant ribociclib to an NSAI does not negatively affect HRQOL in patients with HR+/HER2− early breast cancer.
Year:
2025
Year:
2021
Year:
2021
Collaborators (7)
Sherene Loi
University of Melbourne
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Dennis J. Slamon
University of California, Los Angeles
Peter Fasching
-
Sara Hurvitz
Professor, Division Head
Washington University School of Medicine
Miguel Martin
Universidad Complutense de Madrid
Make your next move.
Prepare your application
Review drafts before you send them.